Geode Capital Management LLC Grows Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Geode Capital Management LLC raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,988,681 shares of the company's stock after acquiring an additional 43,226 shares during the quarter. Geode Capital Management LLC owned approximately 2.30% of IDEAYA Biosciences worth $51,121,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. State Street Corp raised its stake in IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after purchasing an additional 443,640 shares during the period. Barclays PLC raised its position in shares of IDEAYA Biosciences by 188.8% during the third quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of IDEAYA Biosciences in the third quarter worth $246,000. SG Americas Securities LLC boosted its position in shares of IDEAYA Biosciences by 444.2% during the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after acquiring an additional 15,089 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of IDEAYA Biosciences by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock valued at $2,527,000 after purchasing an additional 12,029 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on IDYA. Stephens reaffirmed an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Trading Up 5.6 %

Shares of IDYA stock traded up $0.90 on Friday, reaching $17.08. 1,657,841 shares of the company's stock were exchanged, compared to its average volume of 940,728. The company's fifty day simple moving average is $18.23 and its 200 day simple moving average is $23.86. IDEAYA Biosciences, Inc. has a 52 week low of $13.45 and a 52 week high of $44.42. The stock has a market capitalization of $1.50 billion, a PE ratio of -5.18 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, sell-side analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.